News

Meet the glimins: Poxel raises €13m
Enlarge image

DiabetesFranceSwitzerlandGermany

Meet the glimins: Poxel raises €13m

19.12.2012 - Poxel has successfully closed a Series B financing round. A big share of the €13m will go into the research of glimins, a new anti-diabetics class.

This pill tastes like sugar. Investors of French Poxel SA believe in the biotech’s oral anti-diabetic drug and invest another €13m in a Series B round. Poxel from Lyon announced the news on 18 December. The financing, led by Edmond de Rothschild Investment Partners (EdRIP), included all existing investors such as the InnoBio fund managed by CDC Enterprises within FSI France Investment programme and Omnes Capital (formerly Crédit Agricole Private Equity). According to the press release, a significant part of the funds will be used to confirm efficacy data of the company's lead programme, Imeglimin. The drug is the first in a new Tetrahydrotriazine-containing class of oral anti-diabetics, the glimins.

Poxel was established in 2009, when German Merck KGaA merged with Swiss Serono. The company’s platform are those drug candidates for metabolic diseases that Merck-Serono elected not to continue. In 2010 Poxel raised €16m. Now, with refilled pockets, the small company is about to bring Imeglimin through Phase II trials as a monotherapy and as an add-on therapy to the main anti-diabetic agents, starting with metformin and sitagliptin. However, a crucial Phase IIb study starts in early 2013, when Imeglimin's efficacy profile as a monotherapy treatment will be evaluated in a large six-month trial involving 400 diabetic patients.

Imeglimin has a mitochondria-based mechanism of action, targeting the respiratory chain. It acts on the three key defects of Type 2 diabetes, inhibiting hepatic gluconeogenesis, increasing muscle glucose uptake and restoring normal insulin secretion. Thierry Hercend, MD, PhD and Chairman of the board believes that Imeglimin has the „potential to become a new anti-diabetic standard treatment.”

© eurobiotechnews.eu/ml

http://www.european-biotechnology-news.com/news/news/2012-04/meet-the-glimins-poxel-raises-eur13m.html

BusinessUKSwitzerland

29.07.2015 Newly founded Mereo BioPharma has acquired three mid-stage clinical assets from Novartis. In turn, the Swiss pharma concern will hold a stake in the UK company. Other investors are also on board.

M&AIreland

28.07.2015 Irish Allergan is bolstering its product pipeline with a takeover of CNS specialist Naurex. At the same time, the company is divesting its global generics business to Teva.

Public marketGermanyFranceBelgiumFinlandDenmarkUK

24.07.2015 Biotech companies across Europe continue to raise cash on the public markets, generating €3bn in total financing proceedings in the first half of 2015. Compared to 2014, this is almost twice as much.

FinanceFrance

23.07.2015 US money keeps flowing into Europe's biotechs. As the race for the peanut allergy market heats up, NASDAQ listed French biotech DBV has announced the successful closing of US$281m (€256m) share offering for its allergy products.

BioplasticsFrance

21.07.2015 French biotech Deinove has launched a R&D programme to produce the versatile chemical intermediate muconic acid by using a designer variant of the Deinococcus bacteria.

BusinessFrance

16.07.2015 Sanofi has announced plans to restructure its business in five standalone global business units starting in January 2016. The goal is to promote growth and help the company launch a catalogue of new drugs over the next five years.

R&DUK

15.07.2015 GlaxoSmithKline (GSK) has become the first drugmaker to join the Francis Crick Institute. It is a consortium made up of six scientific and academic institutes to conduct research and drug development in the UK. The new institute is set to become a world-leading centre of biomedical research and innovation.

FundingUK

13.07.2015 UK drug developer ReNeuron has pulled in £68.4m (€96m) for its cell therapy pipeline for stroke and blindness treatments. Biotech guru Neil Woodford increases his fund’s stake in ReNeuron.

BusinessSweden

10.07.2015 Karolinska Development has slashed the reported value of its portfolio by almost half by revising its valuation model for early stage companies and divesting its shares in pain med maker Pharmanest.

M&AIreland

08.07.2015 Horizon Pharma plc. has set its sights on US-American speciality pharma company Depomed Inc. After getting nowhere with the rival’s board, Horizon has now launched a US$3bn hostile bid for the pain and CNS specialist.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • PROTHENA PLC (IE)68.70 USD9.45%
  • HYBRIGENICS (F)1.63 EUR9.40%
  • PHARMING (NL)0.34 EUR6.25%

FLOP

  • SERODUS (N)2.60 NOK-15.58%
  • ZELTIA (E)3.69 EUR-8.44%
  • IXICO (UK)33.00 GBP-7.04%

TOP

  • DBV TECHNOLOGIES (F)77.15 EUR48.7%
  • IXICO (UK)33.00 GBP46.7%
  • ADOCIA (F)90.05 EUR34.0%

FLOP

  • BIOTEST (D)25.67 EUR-63.3%
  • CHRONTECH PHARMA (S)0.01 SEK-50.0%
  • BIOTECH PHARMACON (N)9.35 NOK-45.6%

TOP

  • ADOCIA (F)90.05 EUR553.0%
  • FORMYCON (D)27.30 EUR298.5%
  • DBV TECHNOLOGIES (F)77.15 EUR292.4%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-88.9%
  • NEOVACS (F)1.05 EUR-70.1%
  • NEUROVIVE PHARMACEUTICAL AB (S)21.70 SEK-69.0%

No liability assumed, Date: 29.07.2015